BRCA1 and ovarian carcinoma: However, the ARIEL2 trial assessing rucaparib in monotherapy in platinum-sensitive recurrent ovarian cancer patients showed a median PFS of 12.8 months and an ORR of 80% in the BRCA1/2-mutated population (116) This suggests that the addition of durvalumab might have only a limited impact, if any, on top of PARPi therapy.